Follicular Lymphoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Follicular Lymphoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-19 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Follicular Lymphoma
most recently updated first55 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | $545.6B | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs) | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | 2021-09-13 | Nov 2026 | ≤ 102 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaNCT05100862Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC) | Phase 3 | Active, not recruiting | Drug: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab | Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | 799 | 2022-03-10 | Jul 2028 | ≤ 711 d | 2026-08-19 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaNCT06149286Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide | Phase 3 | Recruiting | Drug: Odronextamab, Lenalidomide, Rituximab | Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | 580 | 2023-12-28 | 2031-04-30 | in 1,714 d | 2026-08-14 |
| AZN | AstraZeneca | — | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLNCT06526793Overall response rate (ORR) (central review) | Phase 2 | Recruiting | Drug: Surovatamig | B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL) | 270 | 2024-11-27 | 2028-04-21 | in 610 d | 2026-08-13 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06980116Number of Participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: EXS73565 | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM) | 85 | 2025-03-31 | Jun 2028 | ≤ 680 d | 2026-08-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaNCT06091254Incidence of Dose-Limiting Toxicities (DLTs) for odronextamab | Phase 3 | Recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine | Follicular Lymphoma (FL) | 822 | 2023-12-12 | 2028-02-07 | in 536 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersNCT07226843Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities | Phase 1 | Recruiting | Drug: LY4584180, Rituximab | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | 2026-04-17 | Apr 2027 | ≤ 253 d | 2026-08-06 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886observationalPrimary Outcome - Blood and Residual Tissue Specimen Collection from 160 Completed Participants for Blood-Based Cancer Monitoring and Detection and Cancer Assay Development. | — | Recruiting | — | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Transformed Follicular Lymphoma, Follicular Lymphoma Grade 3B, Follicular Lymphoma, Anaplastic Large Cell Lymphoma | 200 | 2026-07-27 | Apr 2032 | ≤ 2,080 d | 2026-08-06 |
| PFE | Pfizer | $155.3B | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2018-04-17 | 2028-04-20 | in 609 d | 2026-07-29 |
| TEM | Tempus AI | $8.6B | A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesNCT07154823observationalTo assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications. | — | Recruiting | Other: None - Observational Study | Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | 550 | 2026-01-27 | Nov 2034 | ≤ 3,024 d | 2026-07-21 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589Part 1: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns. | Drug: BGB-21447 | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma | 51 | 2023-06-20 | 2026-06-08actual | — | 2026-07-14 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328Phase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199 | Phase 1 | Recruiting | Drug: LY4152199 - IV | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell | 215 | 2026-05-28 | Apr 2027 | ≤ 253 d | 2026-07-10 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicities | Phase 1 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | 572 | 2022-04-13 | Jan 2027 | ≤ 164 d | 2026-07-02 |
| AZN | AstraZeneca | — | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaNCT04594642Incidence of subjects with Dose-limiting toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: AZD0486 IV | B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma | 226 | 2021-03-02 | 2028-06-19 | in 669 d | 2026-06-17 |
| IPN.PA | Ipsen | $15.5B | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two TherapiesNCT07282548observationalReal-world Objective Response Rate (rwORR) stratified by EZH2 mutation status. | — | Withdrawnsponsor's stated reason: Withdrawn prior to enrolment after review of updated safety data | — | Follicular Lymphoma | 0 | Jun 2026 | 2031-06-30 | in 1,775 d | 2026-04-29 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNCT04830137Number of Participants with Protocol Specified Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: NX-2127 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL) | 248 | 2021-05-05 | May 2026 | — | 2026-03-20 |
| ALLO | Allogene Therapeutics | $701M | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaNCT03939026Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501 | Phase 1 | Completed | Genetic: ALLO-501 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide | Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma | 50 | 2019-05-01 | 2021-10-23actual | — | 2026-03-02 |
| ABBV | AbbVie | $457.5B | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaNCT06830759observationalPercentage of Participants Achieving Overall Response (OR) | — | Recruiting | — | Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 700 | 2025-03-28 | Sep 2031 | ≤ 1,867 d | 2026-02-17 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaNCT06097364Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy | Phase 3 | Active, not recruiting | Drug: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone | Follicular Lymphoma (FL) | 733 | 2023-11-14 | 2029-07-29 | in 1,074 d | 2026-02-06 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)NCT05512390Number of Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: ABBV-319 | Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 154 | 2023-04-26 | Feb 2027 | ≤ 192 d | 2026-01-16 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanNCT05228158observationalNumber of Participants With Adverse Drug Reactions (ADRs) | — | Active, not recruiting | Drug: Tazemetostat | Lymphoma, Follicular | 145 | 2021-08-16 | 2028-03-31 | in 589 d | 2026-01-02 |
| INCY | Incyte Corporation | $24.7B | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.NCT04680052results2025-04-04FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First | Phase 3 | Active, not recruiting | Drug: tafasitamab, rituximab, lenalidomide, placebo | Follicular Lymphoma, Marginal Zone Lymphoma | 654 | 2021-04-15 | 2024-02-23actual | — | 2025-12-22 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesNCT05643742Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities | Phase 1/2 | Recruiting | Biological: CTX112 | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma | 120 | 2023-03-10 | Jan 2030 | ≤ 1,260 d | 2025-11-14 |
| BPTH | Bio-Path Holdings, Inc. | $2M | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesNCT04072458Identify Dose Limiting Toxicity (DLT) of BP1002 | Phase 1 | Active, not recruiting | Drug: L-Bcl-2 antisense oligonucleotide | Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL | 30 | 2020-11-05 | Apr 2025 | — | 2025-02-24 |
| ADPT | Adaptive Biotechnologies | $3.9B | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyNCT05255354observationalPrimary Outcome: Predicting Progression Free Survival | — | Recruiting | Device: ClonoSEQ | Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma | 300 | 2022-06-01 | 2025-09-01 | — | 2024-08-22 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04806035RP2D | Phase 1 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: TG-1801, Ublituximab | CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL | 21 | 2021-04-28 | 2024-06-12actual | — | 2024-07-31 |
| STRO | Sutro Biopharma, Inc. | $365M | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesNCT03424603Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001) | Phase 1 | Completed | Drug: STRO-001 | B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors | 70 | 2018-02-22 | 2024-02-15actual | — | 2024-06-11 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| AMGN | Amgen | $229.9B | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaNCT03571828results2024-03-22Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: Amgen decided to discontinue study because of a business decision and not because of safety reasons | Drug: AMG 562 | Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) | 10 | 2018-10-29 | 2022-01-12actual | — | 2024-03-22 |
| PRLD | Prelude Therapeutics | $459M | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesNCT05107856Dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: PRT1419, Azacitidine, Venetoclax | Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma | 21 | 2022-03-22 | 2024-01-19actual | — | 2024-01-31 |
| ADCT | ADC Therapeutics S.A. | $131M | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaNCT04699461results2023-10-23Complete Response Rate (CRR) | Phase 2 | Terminatedsponsor's stated reason: Administrative decision (not due to safety reason) | Drug: Loncastuximab Tesirine, Idelalisib | Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | 6 | 2021-11-04 | 2022-11-25actual | — | 2023-10-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular LymphomaNCT05338879observationalObjective response rate | — | Completed | Other: Non-Interventional | Relapsed/Refractory Follicular Lymphoma | 247 | 2022-06-22 | 2023-10-05actual | — | 2023-10-18 |
| AGEN | Agenus Inc. | $339M | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaNCT00081809 | Phase 2 | Completed | Drug: autologous human tumor-derived HSPPC-96 | Lymphoma, Follicular, Lymphoma, Small Lymphocytic | 35 | Mar 2000 | Jun 2005actual | — | 2023-09-28 |
| GILD | Gilead Sciences | $177.9B | Dose Optimization Study of Idelalisib in Follicular LymphomaNCT02536300results2023-08-14Overall Response Rate (ORR) | Phase 3 | Terminatedsponsor's stated reason: Gilead has made the decision to close the study due to enrollment challenges | Drug: Idelalisib | Follicular Lymphoma | 96 | 2016-01-14 | 2022-09-27actual | — | 2023-08-14 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaNCT03828448results2023-07-24Overall Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Strategic/Business Decision | Drug: Ublituximab, Umbralisib | Follicular Lymphoma, Small Lymphocytic Lymphoma | 34 | 2019-07-10 | 2022-05-16actual | — | 2023-07-24 |
| FATE | Fate Therapeutics | $307M | FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaNCT05934097Incidence of dose-limiting toxicities within each dose escalation cohort | Phase 1 | Withdrawnsponsor's stated reason: This study was withdrawn (Sponsor decision). | Drug: FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Bendamustine | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 0 | Dec 2022 | May 2026 | — | 2023-07-06 |
| TGTX | TG Therapeutics, Inc. | $7.7B | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaNCT02793583Overall Response Rate | Phase 2/3 | Terminatedsponsor's stated reason: Strategic/Business Decision | Biological: Ublituximab, Bendamustine · Drug: Umbralisib | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma | 710 | 2016-05-25 | 2022-05-31actual | — | 2022-07-21 |
| INCY | Incyte Corporation | $24.7B | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)NCT04796922Progression Free Survival (PFS) in R/R FL and MZL participants | Phase 3 | Withdrawnsponsor's stated reason: This study was withdrawn due to a business decision. | Drug: parsaclisib, rituximab, obinutuzumab | Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | 0 | 2022-12-30 | 2028-12-20 | in 853 d | 2022-07-18 |
| ADCT | ADC Therapeutics S.A. | $131M | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaNCT03685344results2021-10-26Number of Participants With a Treatment-emergent Adverse Event (TEAE) | Phase 1 | Terminatedsponsor's stated reason: In a limited number of patients, no additional activity was evident for the combination vs. loncastuximab tesirine monotherapy. | Drug: Loncastuximab Tesirine and Durvalumab | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | 13 | 2019-02-04 | 2020-10-27actual | — | 2021-10-26 |
| GILD | Gilead Sciences | $177.9B | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLNCT01728207Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | Phase 1 | Terminatedsponsor's stated reason: Study was stopped due to insufficient efficacy and very slow accrual | Drug: IMMU-114 | Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 30 | Mar 2013 | Mar 2017actual | — | 2021-08-19 |
| GILD | Gilead Sciences | $177.9B | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLNCT00546793Safety/tolerability | Phase 1/2 | Completed | Biological: veltuzumab | NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Intermediate-Grade, Lymphoma, Large-Cell, Lymphoma, Low-Grade, Lymphoma, Mixed-Cell, Lymphoma, Small-Cell, Leukemia, Lymphocytic, Chronic, Leukemia, B-Cell, Chronic, Leukemia, Prolymphocytic, Leukemia, Small Lymphocytic, Lymphoma, Small Lymphocytic, Lymphoma, Lymphoplasmacytoid, CLL, Lymphoplasmacytoid Lymphoma, CLL, CLL, SLL | 32 | Jan 2008 | Mar 2013actual | — | 2021-08-16 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)NCT02669017results2020-04-13Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Phase 1 | Completed | Drug: ADCT-402 | Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma | 183 | Mar 2016 | 2019-02-21actual | — | 2021-05-19 |
| 068270.KS | Celltrion | $30.7B | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular LymphomaNCT02260804results2021-04-08Primary Efficacy Endpoint - Overall Response Rate by 7 Months | Phase 3 | Completed | Biological: CT-P10, Rituxan | Follicular Lymphoma | 258 | 2015-11-09 | 2018-01-04actual | — | 2021-04-08 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)NCT02242045results2021-03-19Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure | Phase 1 | Completed | Drug: Idelalisib | Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia), Marginal Zone Lymphoma | 6 | 2014-10-01 | 2014-12-25actual | — | 2021-03-19 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesNCT01799889results2020-09-23Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | Phase 2 | Terminatedsponsor's stated reason: Sponsor's decision to discontinue development of entospletinib. | Drug: Entospletinib MM, Entospletinib SDD | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | 326 | 2013-03-14 | 2017-09-14actual | — | 2020-11-19 |
| PFE | Pfizer | $155.3B | A Study Of PF-05082566 As A Single Agent And In Combination With RituximabNCT01307267results2020-03-17Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A | Phase 1 | Completed | Drug: PF-05082566, rituximab, PF-05082566 | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma | 190 | 2011-06-21 | 2019-02-20actual | — | 2020-03-17 |
| 068270.KS | Celltrion | $30.7B | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With RituxanNCT02162771results2020-01-29Area Under the Serum Concentration-time Curve at Steady State (AUCtau) | Phase 3 | Completed | Biological: Rituxan, CT-P10 · Drug: Cyclophosphamide, Vincristine, Prednisone | Lymphoma, Follicular | 140 | 2014-07-14 | 2016-01-12actual | — | 2020-01-29 |
| GILD | Gilead Sciences | $177.9B | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasNCT01282424results2014-09-04Overall Response Rate | Phase 2 | Completed | Drug: Idelalisib | Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma | 125 | 2011-03-18 | 2018-05-02actual | — | 2019-07-11 |
| PFE | Pfizer | $155.3B | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)NCT02213263results2018-10-30Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 | Phase 3 | Completed | Biological: PF-05280586, MabThera® | Follicular Lymphoma | 394 | 2014-09-30 | 2017-10-23actual | — | 2019-06-20 |
| GILD | Gilead Sciences | $177.9B | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaNCT02258529results2017-05-18Overall Response Rate | Phase 2 | Terminated | Drug: Idelalisib · Biological: Rituximab | Follicular Lymphoma, Small Lymphocytic Lymphoma | 10 | 2015-09-14 | 2016-04-12actual | — | 2019-05-14 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaNCT01306643results2016-12-21Overall Safety of Idelalisib | Phase 1/2 | Completed | Drug: Idelalisib | Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma | 18 | Feb 2011 | Aug 2015actual | — | 2018-11-19 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Enzastaurin in Participants With Follicular LymphomaNCT00475644results2018-11-05Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) | Phase 2 | Completed | Drug: Enzastaurin | Lymphoma, Follicular | 66 | May 2007 | Apr 2012actual | — | 2018-11-05 |
| PFE | Pfizer | $155.3B | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)NCT00562965results2018-01-09Progression-Free Survival (PFS) | Phase 3 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: inotuzumab ozogamicin, rituximab, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone | Lymphoma, Follicular | 29 | Nov 2007 | Apr 2011actual | — | 2018-01-09 |
| GILD | Gilead Sciences | $177.9B | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaNCT02258555Occurrence of adverse events (AEs) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs) | Phase 1 | Terminated | Drug: GS-9901 | Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma | 7 | Jan 2015 | Aug 2015actual | — | 2015-10-19 |
| BMY | Bristol-Myers Squibb | $134.9B | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersNCT01120457Safety and tolerability as monotherapy | Phase 1 | Completed | Drug: BMS-936564 (Anti-CXCR4) | Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 96 | Aug 2010 | Nov 2014actual | — | 2015-03-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Follicular Lymphoma is matched — 7 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Follicular Lymphoma
- Lymphoma, Follicular
- Follicular Lymphoma (FL)
- Relapsed/Refractory Follicular Lymphoma
- Follicular Lymphoma ( FL)
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Follicular Lymphoma” (a text search, wider than this page)